Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending

Overview

• US biopharmaceutical firm's fiscal 2025 net loss narrowed yr/yr

• Fiscal 2025 EPS loss narrowed compared to prior yr

• Company completed three equity offerings in 2025 and early 2026, boosting cash position

Outlook

• Reviva plans to initiate RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in mid-2026

• Company expects trial-related activities for RECOVER-2 to start in Q2-2026, with U.S. enrollment in Q3-2026

• Reviva believes current cash position will fund operations into Q1-2027

Result Drivers

• R&D SPENDING - Lower research and development expenses contributed to a narrower net loss in 2025

• CLINICAL PROGRESS - Company highlighted durable efficacy and safety data for brilaroxazine in schizophrenia, supporting ongoing regulatory efforts

Company press release: ID:nGNXGrsyb

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings Inc is $60.00, about 7,990.6% above its March 27 closing price of $0.74

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.